What is CommonQuant (Common Quant)?

CommonQuant, also written Common Quant, is an AI-powered trading platform that turns plain-English market ideas into live, rules-based strategies. It selects relevant instruments, writes indicator-based entry and exit rules, monitors the conditions continuously, and alerts users when conditions are met.

How does CommonQuant generate trading strategies?

You write a natural-language prompt describing your market idea. CommonQuant selects validated instruments, chooses from 20 supported technical indicators, and writes concrete entry and exit rules. The strategy then runs live and sends alerts through the channels available on your plan when conditions trigger.

What markets and instruments does CommonQuant support?

CommonQuant supports several thousand US equities and ETFs listed on Nasdaq, NYSE, NYSE American, and Cboe, plus major crypto assets such as Bitcoin. It does not support FX or futures.

How do I receive trading signal alerts?

CommonQuant provides an in-app signal inbox on all plans. Paid plans add email and Telegram, plus metered monthly SMS and WhatsApp allowances. Channel availability and allowances vary by plan.

Is CommonQuant free to use?

Yes. CommonQuant has a free tier with 1,000 starter credits, 200 monthly refill credits, up to three signal subscriptions, and in-app alerts. Paid plans start at $9/month, and no credit card is required to start.

Does CommonQuant provide financial advice?

No. CommonQuant is a quantitative tool for alpha validation and does not constitute financial advice. Past performance does not guarantee future results. Users are responsible for their own trading decisions.

Can I copy public trading strategies?

Yes. Users can browse, preview, and copy public community and AI-generated strategies into their own accounts. They can also follow strategists and take part in Arena competitions.

CommonQuant.ai Research

AI-generated trading idea · LONG · ABBV, APOG, XBI

AbbVie drops $10.9B on Apogee — ride the biotech buyout premium

Drug giant AbbVie just announced it is buying Apogee Therapeutics for $10.9 billion to expand its immunology portfolio.

Idea

When a massive pharmaceutical company buys a smaller biotech, it often signals a broader rush by big pharma to snap up promising drug developers. This could spark a wave of speculation in other small and mid-sized biotech firms with similar immunology or next-generation treatments, as traders bet they could be the next takeover targets.

Key details

ABBV APOG XBI1D#biotech#ma#catalyst

Community

Upvotes

Views

Copies

Cosigns

News sources

AbbVie bets $10.9 billion on Apogee in next-generation immunology growth push — CNBC

Related ideas

Vertex drops $10B to dominate hormone treatments — ride the acquisition momentum
AstraZeneca's heart drug flops in trials — short the failed-drug fallout

ABBV trade ideas
APOG trade ideas
XBI trade ideas
Latest market news